Q3 2020 FINANCIAL RESULTS

November 5, 2020

DISCLAIMER

This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. By receiving this presentation and/or attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations. This presentation is being made only to, and is directed only at, (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the United Kingdom Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) (the “Order”); (ii) high net worth bodies corporate, unincorporated associations, partnerships and trustees of high value trusts as described in Article 49(2)(a)-(d) of the Order; (iii) “overseas recipients” as defined in Article 12 of the Order; (iv) persons in member states of the European Economic Area (the “EEA”) who are qualified investors, as defined in the Prospectus Regulation (Regulation (EU) 2017/1129) (as amended); (v) qualified institutional buyers in the United States as defined in Rule 144A of the United States Securities Act of 1933; or (vi) persons to whom it would otherwise be lawful to distribute it (all such persons being “Relevant Persons”). Persons who receive this communication (other than Relevant Persons) should not rely on or act upon the contents of this presentation and should return this document immediately. This presentation is being directed only at Relevant Persons and any investment or investment activity to which this presentation relates will be engaged in only with Relevant Persons. This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this presentation or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment activity (including within the meaning specified in section 21 of the United Kingdom Financial Services and Markets Act 2000), nor does it constitute a recommendation regarding the securities of the Group. Securities of the abovementioned persons or any of their respective affiliates have not been registered under United States securities laws and may not be offered or sold in the United States absent registration under such laws or unless exempt from registration under such laws. Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel. Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in the United States, Canada, Australia, Japan or any other jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation. Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this presentation. No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this presentation or any other written or oral information which has been or may be made available. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the presentation. No reliance whatsoever may be placed on the presentation for any purpose. The Company’s shares are currently admitted to trading on public exchanges and, therefore, certain of the information in this presentation could constitute inside information and/or price sensitive information. By accepting this presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws. The information contained in this presentation has not been independently verified. The information in this presentation includes forward-looking statements, made in good faith, which are based on the Group’s or, as appropriate, the Group’s directors' current expectations and projections about future events. These forward-looking statements may be identified by the use of forward-looking terminology including, but not limited to, the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussion of the Group’s strategy, plans, operations, financial performance and condition, objectives, goals, future events or intentions. These forward-looking statements, as well as those included in any other material discussed at the meeting, are subject to risks, uncertainties and assumptions about the Group and investments many of which are outside of the Group’s control, including, among other things, the development of its business, the trends in its operating industry, changing economic, financial, or other market conditions and future capital expenditures. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may differ materially from those indicated in these statements. Forward-looking statements may, and often do, materially differ from actual results. Thus, these forward-looking statements should be treated with caution and the recipients of the presentation should not place undue reliance on any forward-looking statements. None of the future projections, expectations, estimates or prospects or any other statements contained in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the Company’s future financial performance. The Company’s past performance cannot be relied on as a guide to future performance. Any forward looking-statements are made as of the date hereof. The information and opinions contained in this presentation and any other material discussed verbally are provided as at the date of this presentation and are subject to verification, completion and change without notice. The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the AIM Rules for Companies published by London Stock Exchange plc and the Market Abuse Regulation (Regulation (EU) 596/2014) (each as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent. Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice. This presentation may include certain combined or pro forma financial information for the Company. Such combined or pro forma financial information is preliminary in nature, remains subject to change and is provided solely for illustrative purposes. No reliance should be placed on the combined or pro forma financial information contained in this presentation. By requesting to receive and reviewing this document, you agree to be bound by the foregoing limitations and conditions and, in particular, will be deemed to have represented, warranted and undertaken that you have read and agree to comply with the contents of this disclaimer.

The Amryt logo, MYALEPT®, MYALEPTA®, JUXTAPID®, LOJUXTA®, FILSUVEZ® and other trademarks or service marks of Amryt appearing in this presentation are the property of Amryt. This presentation includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this presentation appear without the ®, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. FILSUVEZ® (Oleogel-S10/formerly known as AP101) is currently an investigational product and has not received regulatory approval by the FDA or EMA. Elements of this presentation only apply in the event that FILSUVEZ® is approved by the appropriate regulatory authorities.

Q3 2020 HIGHLIGHTS

- Commercial products continue to perform and grow beyond expectations
- 19% YoY growth in Revenue to $49.3M
- 96% QoQ growth in EBITDA to $13.5M
- Raising full year guidance to $180M - $182M (prior guidance was $170M - $175M)
- Positive results from pivotal Phase 3 EASE trial of FILSUVEZ®* in Epidermolysis Bullosa

* FILSUVEZ® has been selected as the brand name for the product. Note: Amryt does not, as yet, have regulatory approval for FILSUVEZ® to treat EB

STRONG REVENUE PERFORMANCE

COMMERCIAL PRODUCTS PERFORMING AND GROWING





- EBITDA** of $13.5M in Q3 - 96% QoQ growth
- $21.1M of cash generated from operating activities during the nine months ended September 2020
- $75.4M cash at September 30, 2020 versus $67.1M at June 30, 2020

* 2019 reflects pro forma revenues for the combined group
** EBITDA is earnings before interest, tax, depreciation, amortization and share based compensation expenses

AMRYT PHARMA

METRELEPTIN



- 31% growth in Myalept® / Myalepta® (metreleptin) revenues to $29.9M in the quarter (Q3 2019: unaudited combined revenues* $22.9M)
- Metreleptin revenues were bolstered by a $6.9M order in LATAM during Q3 2020
- June 2020: Appointed Swixx BioPharma AG as exclusive distributor of Myalepta® (metreleptin) across the CEE territories

Label Expansion Initiatives

- Seek label expansion to include the treatment of partial lipodystrophy (PL) in US
- Adding PL would effectively double the size of the U.S. addressable market from $140M to $280M**

*Reflects pro forma revenues for the combined group
** Management estimate

LOMITAPIDE



- 4% increase in Juxtapid®/Lojuxta® (lomitapide) revenues to $19.1M in the quarter (Q3 2019: unaudited combined revenues* $18.3M)
- October 2020: signed a distribution agreement for Lojuxta® (lomitapide) with Swixx BioPharma AG across 17 jurisdictions in Central and Eastern Europe

Label Expansion Initiatives

- Pediatric HoFH: PIP agreed with EMA; Phase 3 EU data expected in H1 2022
- FCS: Physician sponsored 18 patient study underway in Northern Italy. Label expansion into FCS would potentially double the addressable market**

* Reflects pro forma revenues for the combined group
** Management estimate

AMRYT PHARMA

EASE RESULTS SUMMARY

- Largest ever Phase 3 RCT [1] performed in EB
- The primary endpoint demonstrated a statistically significant acceleration of target wound healing by day 45 in patients treated with FILSUVEZ® vs control gel (p=0.013)[2]
  - The RDEB[3] sub-group was observed to experience a greater benefit when treated with FILSUVEZ® than the overall population (nominal p=0.008)
- Favourable trends were evident among secondary endpoints including procedural pain, change in EBDASI [3] score and BSAP [3]
- FILSUVEZ® had an acceptable safety profile and was well tolerated when compared with control gel

FILSUVEZ® represents a potentially important advancement for patients and families living with this intractable skin disease

1. Randomised Controlled Trial
2. Pre-specified adjustment to account for IDMC interim sample size re-estimation;
3. RDEB; Recessive Dystrophic EB; EBDASI, Epidermolysis Bullosa Disease Activity and Scarring Index; BSAP, Body Surface Area Percentage

EASE TRIAL MET ITS PRIMARY ENDPOINT



44% increase in target wound closure with FILSUVEZ® vs control gel

*Pre-specified adjustment to account for IDMC interim sample size re-estimation
CI, confidence interval; EB, epidermolysis bullosa

RDEB SUBGROUP DRIVES PRIMARY ENDPOINT TREATMENT EFFECT

Relative risk [95%CI], 1.72 [1.14, 2.59]

Odds ratio [95%CI], 2.52 [1.27, 4.98]



72% increase in target wound closure in RDEB patients with FILSUVEZ vs control gel

*Nominal P values

** RDEB, Recessive Dystrophic EB; DDEB, Dominant Dystrophic EB; JEB, Junctional EB

AMRYT PHARMA

FILSUVEZ® - US & EUROPEAN ANTICIPATED REGULATORY TIMELINES

NDA TIMELINE – FDA – 6 MONTH PRIORITY REVIEW AND ROLLING NDA

2020

January

Apr - Type C meeting completed

Jun - Module 3 CMC request for priority review submitted

Sept – Positive Top Line Phase 3 Results w/ primary endpoint met

Dec- pre-NDA meeting

December

2021

January

Mar - Initial submission

May - Filing Date

Nov - Anticipated Approval Date

Nov – Priority Review Voucher

December

MAA TIMELINE – EMA – ACCELERATED ASSESSMENT

2020

January

Jun – MAA Letter of Intent submitted to EMA

Sep – Rapporteurs assigned by CHMP

Nov – MAA Pre-submission meetings

Dec – Accelerated Assessment request to CHMP

December

2021

January

Mar - Initial submission (Accelerated Review Schedule)

Jun - List of Questions (LoQ) received

Aug - Submission of responses to LOQ

Sep - List of Outstanding Issues (LoOI) received and responses submitted

Oct - CHMP Opinion

Dec - European Commission Decision

December

FILSUVEZ® LAUNCH READINESS

- Amryt is a commercial stage company with a track record of delivering on commercial targets
- EB is a severe debilitating disease for which there are no approved treatments
- The EB market is highly concentrated and feasible to reach with limited incremental resources
- There is a significant market opportunity if FILSUVEZ® were approved by regulatory authorities
- Amryt is developing robust launch plans* to access the opportunity based on our commercial infrastructure, rare disease philosophy, experience and playbook
- Manufacturing scale up & supply chain plan in place to ensure adequate drug supply to meet demand
- FILSUVEZ® benefits from strong patent protection and exclusivity enabling Amryt to create significant value in EB and beyond
- Amryt is building a global EB Franchise to serve patients in desperate need of new treatments

*If FILSUVEZ® were to be approved by regulatory authorities

Q3 2020 FINANCIALS

RORY NEALON

Chief Financial Officer, Chief Operating Officer

Q3 2020 INCOME STATEMENT

Q3'2020	Actual US$m	Adjustments US$m	As Adjusted US$m
Revenue	**49.3**	**-**	**49.3**
Gross Profit	**22.3**	**15.1**	**37.4**
Gross Margin			*75.9%*
R&D	(7.4)	-	(7.4)
SG&A	(16.9)	0.5	(16.4)
Acquisition & severance related costs	(0.1)	-	(0.1)
Share based compensation expenses	(1.5)	1.5	-
Operating (loss) / profit before finance expense	**(3.6)**	**17.1**	**13.5***

* EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses

DEBT AT SEPTEMBER 30, 2020

$125M Convertible Debt Facility	$86M Term Debt Facility
5.5 year bullet, Apr 2025	5 year bullet, Sep 2024
Unsecured	Secured
Coupon: 5% cash	Coupon: 6.5% cash & 6.5% PIK
Convertible price: $12.95 per ADS; $2.59 per Ord Share	

Questions & Answers

AMRYT PHARMA